Inherited Thrombophilia: Implications for Prevention and Treatment of Venous Thromboembolism

ABSTRACT

Inherited thrombophilia, defined as a genetically determined tendency to develop venous thromboembolism (VTE), contributes to the pathogenesis of ~40% of VTE episodes. About 50% of carriers of inherited thrombophilic traits develop VTE, but the impact of the different abnormalities is variable in terms of clinical penetrance. Some rare abnormalities (natural anticoagulant deficiencies, homozygous factor V Leiden, and combined defects) result in more severe thrombophilic phenotypes, characterized by early-onset events, more frequent recurrence, and positive family history, whereas the common polymorphisms (heterozygous factor V Leiden and prothrombin G20210A) are associated with lower VTE risk, often in association with triggering risk factors. Therefore, clinical implications of inherited thrombophilia should be assessed in the framework of coexisting and/or circumstantial risk factors involved in the multifactorial pathogenesis of VTE. These considerations should be taken into account when assessing the need and modalities of primary and secondary thromboprophylaxis in patients carrying inherited thrombophilic traits.

KEYWORDS

Antithrombotic treatment - thrombophilia - thromboprophylaxis - risk factors - venous thromboembolism - review

REFERENCES

• 1 Heit J A. Venous thromboembolism: disease burden, outcomes and risk factors.  J Thromb Haemost. 2005;  3(8) 1611-1617
• 2 Naess I A, Christiansen S C, Romundstad P, Cannegieter S C, Rosendaal F R, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study.  J Thromb Haemost. 2007;  5(4) 692-699
• 3 Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallon W M, Melton III L J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.  Arch Intern Med. 1998;  158(6) 585-593
• 4 Geerts W. Prevention of venous thromboembolism: a key patient safety priority.  J Thromb Haemost. 2009;  7(Suppl 1) 1-8
• 5 Goldhaber S Z. Venous thromboembolism prophylaxis: quality, location (hospital vs. home), and duration.  Thromb Haemost. 2009;  102(1) 1-2
• 6 Jordan F LJ, Nandorff A. The familial tendency in thrombo-embolic disease.  Acta Med Scand. 1956;  156(4) 267-275
• 7 Egeberg O. Inherited antithrombin deficiency causing thrombophilia.  Thromb Diath Haemorrh. 1965;  13 516-530
• 8 Griffin J H, Evatt B, Zimmerman T S, Kleiss A J, Wideman C. Deficiency of protein C in congenital thrombotic disease.  J Clin Invest. 1981;  68 1370-1373
• 9 Comp P C, Esmon C T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S.  N Engl J Med. 1984;  311(24) 1525-1528
• 10 Dahlbäck B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.  Proc Natl Acad Sci U S A. 1993;  90(3) 1004-1008
• 11 Bertina R M, Koeleman B PC, Koster T et al.. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature. 1994;  369(6475) 64-67
• 12 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;  88(10) 3698-3703
• 13 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet. 1999;  353(9159) 1167-1173
• 14 Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over.  Semin Thromb Hemost. 2008;  34(8) 747-761
• 15 Heit J A, Silverstein M D, Mohr D N, Petterson T M, O'Fallon W M, Melton III L J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.  Arch Intern Med. 2000;  160(6) 809-815
• 16 Samama M M, Dahl O E, Quinlan D J, Mismetti P, Rosencher N. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.  Haematologica. 2003;  88(12) 1410-1421
• 17 Lane D A, Mannucci P M, Bauer K A et al.. Inherited thrombophilia: Part 1.  Thromb Haemost. 1996;  76(5) 651-662
• 18 Martinelli I, Cattaneo M, Taioli E, De Stefano V, Chiusolo P, Mannucci P M. Genetic risk factors for superficial vein thrombosis.  Thromb Haemost. 1999;  82(4) 1215-1217
• 19 Margaglione M, Brancaccio V, Ciampa A, Papa M L, Grandone E, Di Minno G. Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: distinct roles in different clinical settings.  Haematologica. 2001;  86(6) 634-639
• 20 Martinelli I. Unusual forms of venous thrombosis and thrombophilia.  Pathophysiol Haemost Thromb. 2002;  32(5-6) 343-345
• 21 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis.  N Engl J Med. 2001;  344(16) 1222-1231
• 22 Middeldorp S, Levi M. Thrombophilia: an update.  Semin Thromb Hemost. 2007;  33(6) 563-572
• 23 Rosendaal F R, Reitsma P H. Genetics of venous thrombosis.  J Thromb Haemost. 2009;  7(Suppl 1) 301-304
• 24 Robertson L, Wu O, Langhorne P Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study et al. Thrombophilia in pregnancy: a systematic review.  Br J Haematol. 2006;  132(2) 171-196
• 25 van der Meer F JM, Koster T, Vandenbroucke J P, Briët E, Rosendaal F R. The Leiden Thrombophilia Study (LETS).  Thromb Haemost. 1997;  78(1) 631-635
• 26 Martinelli I, Mannucci P M, De Stefano V et al.. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.  Blood. 1998;  92(7) 2353-2358
• 27 Sanson B-J, Simioni P, Tormene D et al.. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study.  Blood. 1999;  94(11) 3702-3706
• 28 Simioni P, Sanson B-J, Prandoni P et al.. Incidence of venous thromboembolism in families with inherited thrombophilia.  Thromb Haemost. 1999;  81(2) 198-202
• 29 Middeldorp S, Henkens C M, Koopman M M et al.. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis.  Ann Intern Med. 1998;  128(1) 15-20
• 30 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance).  Blood. 1995;  85(6) 1504-1508
• 31 Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci P M. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both.  Br J Haematol. 2000;  111(4) 1223-1229
• 32 Meinardi J R, Middeldorp S, de Kam P J et al.. Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis.  Blood Coagul Fibrinolysis. 2001;  12(8) 713-720
• 33 van Boven H H, Reitsma P H, Rosendaal F R et al.. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency.  Thromb Haemost. 1996;  75(3) 417-421
• 34 Margaglione M, D'Andrea G, Colaizzo D et al.. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism.  Thromb Haemost. 1999;  82(6) 1583-1587
• 35 Vossen C Y, Conard J, Fontcuberta J et al.. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT).  J Thromb Haemost. 2005;  3(3) 459-464
• 36 de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders.  Semin Thromb Hemost. 2009;  35(4) 356-366
• 37 Bezemer I D, Doggen C J, Vos H L, Rosendaal F R. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study.  Arch Intern Med. 2007;  167(5) 497-501
• 38 Eekhoff E M, Rosendaal F R, Vandenbroucke J P. Minor events and the risk of deep venous thrombosis.  Thromb Haemost. 2000;  83(3) 408-411
• 39 Castoldi E, Simioni P, Kalafatis M et al.. Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family.  Blood. 2000;  96(4) 1443-1448
• 40 Palareti G, Leali N, Coccheri S Italian Study on Complications of Oral Anticoagulant Therapy et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT).  Lancet. 1996;  348(9025) 423-428
• 41 Vandenbroucke J P, van der Meer F J, Helmerhorst F M, Rosendaal F R, Factor V. Factor V Leiden: should we screen oral contraceptive users and pregnant women?.  BMJ. 1996;  313(7065) 1127-1130
• 42 Cosmi B, Legnani C, Bernardi F, Coccheri S, Palareti G. Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study.  BMJ. 2001;  322 1024-1025
• 43 Varga E A, Kerlin B A, Wurster M W. Social and ethical controversies in thrombophilia testing and update on genetic risk factors for venous thromboembolism.  Semin Thromb Hemost. 2008;  34(6) 549-561
• 44 Geerts W H, Bergqvist D, Pineo G F American College of Chest Physicians et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, Suppl) 381S-453S
• 45 Patnaik M M, Moll S. Inherited antithrombin deficiency: a review.  Haemophilia. 2008;  14(6) 1229-1239
• 46 Rodgers G M. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update.  Thromb Haemost. 2009;  101(5) 806-812
• 47 Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases.  Thromb Haemost. 1987;  58(4) 1094
• 48 Goldenberg N A, Manco-Johnson M J. Protein C deficiency.  Haemophilia. 2008;  14(6) 1214-1221
• 49 McColl M D, Ramsay J E, Tait R C et al.. Risk factors for pregnancy associated venous thromboembolism.  Thromb Haemost. 1997;  78(4) 1183-1188
• 50 Gerhardt A, Scharf R E, Beckmann M W et al.. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  N Engl J Med. 2000;  342(6) 374-380
• 51 Bates S M, Greer I A, Pabinger I, Sofaer S, Hirsh J. American College of Chest Physicians . Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, Suppl) 844S-886S
• 52 Screening di trombofilia e indicazioni alla profilassi in gravidanza [in Italian]. Linee Guida della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET); last update May 2008. Available at: http://www.siset.org/lineeguida/LG5.pdf
• 53 Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci P M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium.  Thromb Haemost. 2002;  87(5) 791-795
• 54 Vandenbroucke J P, Rosing J, Bloemenkamp K WM et al.. Oral contraceptives and the risk of venous thrombosis.  N Engl J Med. 2001;  344 1527-1535
• 55 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Vandenbroucke J P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects.  Arch Intern Med. 2000;  160 49-52
• 56 Pabinger I, Schneider B. The GTH Study Group on Natural Inhibitors . Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication.  Thromb Haemost. 1994;  71(5) 548-552
• 57 Mohllajee A P, Curtis K M, Martins S L, Peterson H B. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review.  Contraception. 2006;  73(2) 166-178
• 58 Wu O, Robertson L, Langhorne P et al.. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.  Thromb Haemost. 2005;  94(1) 17-25
• 59 Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci P M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.  N Engl J Med. 1998;  338(25) 1793-1797
• 60 van Vlijmen E F, Brouwer J L, Veeger N J, Eskes T K, de Graeff P A, van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study.  Arch Intern Med. 2007;  167(3) 282-289
• 61 Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III.  Thromb Haemost. 1992;  68(6) 634-636
• 62 Chan Y C, Valenti D, Mansfield A O, Stansby G. Warfarin induced skin necrosis.  Br J Surg. 2000;  87(3) 266-272
• 63 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of Chest Physicians . Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, Suppl) 160S-198S
• 64 Prandoni P, Lensing A WA, Cogo A et al.. The long-term clinical course of acute deep venous thrombosis.  Ann Intern Med. 1996;  125(1) 1-7
• 65 Prandoni P, Noventa F, Ghirarduzzi A et al.. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.  Haematologica. 2007;  92(2) 199-205
• 66 Heit J A, Mohr D N, Silverstein M D, Petterson T M, O'Fallon W M, Melton III L J. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.  Arch Intern Med. 2000;  160(6) 761-768
• 67 Kearon C, Kahn S, Agnelli G et al.. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 454S-545S
• 68 Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.  Lancet. 2003;  362(9383) 523-526
• 69 Ho W K, Hankey G J, Quinlan D J, Eikelboom J W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.  Arch Intern Med. 2006;  166(7) 729-736
• 70 Dalen J E. Should patients with venous thromboembolism be screened for thrombophilia?.  Am J Med. 2008;  121(6) 458-463
• 71 Kearon C, Julian J A, Kovacs M J ELATE Investigators et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.  Blood. 2008;  112(12) 4432-4436
• 72 Marchiori A, Mosena L, Prins M H, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.  Haematologica. 2007;  92(8) 1107-1114
• 73 Christiansen S C, Cannegieter S C, Koster T, Vandenbroucke J P, Rosendaal F R. Thrombophilia, clinical factors, and recurrent venous thrombotic events.  JAMA. 2005;  293(19) 2352-2361
• 74 De Stefano V, Martinelli I, Mannucci P M et al.. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.  N Engl J Med. 1999;  341(11) 801-806
• 75 Brouwer J L, Lijfering L M, ten Kate M I et al.. High long term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C, or antithrombin.  Thromb Haemost. 2009;  101 703-710
• 76 Kyrle P A, Minar E, Hirschl M et al.. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.  N Engl J Med. 2000;  343(7) 457-462
• 77 Schulman S, Svenungsson E, Granqvist S. Duration of Anticoagulation Study Group . Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy.  Am J Med. 1998;  104(4) 332-338
• 78 Palareti G, Cosmi B, Legnani C et al.. D-dimer testing to determine the duration of anticoagulant therapy.  N Engl J Med. 2006;  355 1780-1789
• 79 Prandoni P, Lensing A W, Prins M H et al.. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism.  Ann Intern Med. 2002;  137(12) 955-960
• 80 Piovella F, Crippa L, Barone M et al.. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis.  Haematologica. 2002;  87(5) 515-522
• 81 Young L, Ockelford P, Milne D et al.. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality.  J Thromb Haemost. 2006;  4 1919-1924
• 82 Spiezia L, Tormene D, Pesavento R, Salmaso L, Simioni P, Prandoni P. Thrombophilia as a predictor of persistent residual vein thrombosis.  Haematologica. 2008;  93(3) 479-480
• 83 Eichinger S, Kyrle P A. Duration of anticoagulation after initial idiopathic venous thrombosis—the swinging pendulum: risk assessment to predict recurrence.  J Thromb Haemost. 2009;  7(Suppl 1) 291-295
• 84 De Stefano V, Rossi E, Za T, Leone G. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia.  Semin Thromb Hemost. 2006;  32(8) 767-780